Comparison between CIEL HR IPO and Paramesu Biotech IPO.
CIEL HR IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Paramesu Biotech IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
| CIEL HR IPO | Paramesu Biotech IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | Mainboard | Mainboard |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE, NSE | BSE, NSE |
| Lead Managers | HDFC Bank Ltd. Centrum Capital Ltd. Ambit Pvt.Ltd. | Pantomath Capital Advisors Pvt.Ltd. |
| Registrar | Kfin Technologies Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | ||
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | ||
| IPO Allotment URL |
The total issue size of CIEL HR IPO is up to ₹0.00 Cr whereas the issue size of the Paramesu Biotech IPO is up to ₹600.00 Cr. The final issue price of CIEL HR IPO is and of Paramesu Biotech IPO is .
| CIEL HR IPO | Paramesu Biotech IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹5 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹335.00 Cr | up to ₹520.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹80.00 Cr |
| Issue Size Total | 47,39,336 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹600.00 Cr |
CIEL HR IPO opens on , while Paramesu Biotech IPO opens on . The closing date of CIEL HR IPO and Paramesu Biotech IPO is , and , respectively.
CIEL HR IPO P/E ratio is , as compared to Paramesu Biotech IPO P/E ratio of .
| CIEL HR IPO | Paramesu Biotech IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 87.02 | 92.19 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 12.90% | 23.30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 13.18% | 18.13% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.79 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 12.93% | 23.30% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the CIEL HR IPO Retail Individual Investors (RII) are offered while in Paramesu Biotech IPO retail investors are offered . Qualified Institutional Buyers (QIB) are offered in CIEL HR IPO and 0 shares in Paramesu Biotech IPO.
| CIEL HR IPO | Paramesu Biotech IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | 0 shares | |
| QIB | 0 shares | |
| NII | 0 shares | |
| RII | 0 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 0 shares |
CIEL HR IPO subscribed in total, whereas Paramesu Biotech IPO subscribed .
| CIEL HR IPO | Paramesu Biotech IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | ||
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | ||
| Employee (times) | ||
| Other (times) | ||
| Total (times) |
